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Context: Pituitary adenomas and pheochromocytomas/paragangliomas (pheo/PGL) can occur in
the same patient or in the same family. Coexistence of the two diseases could be due to either a
common pathogenic mechanism or a coincidence.
Objective: The objective of the investigation was to study the possible coexistence of pituitary
adenoma and pheo/PGL.
Design: Thirty-nine cases of sporadic or familial pheo/PGL and pituitary adenomas were investigated.
Knownpheo/PGL genes (SDHA-D, SDHAF2,RET,VHL, TMEM127,MAX, FH) andpituitary adenomagenes
(MEN1,AIP,CDKN1B)weresequencedusingnextgenerationorSangersequencing.Lossofheterozygosity
study and pathological studies were performed on the available tumor samples.
Setting: The study was conducted at university hospitals.
Patients: Thirty-nine patients with sporadic of familial pituitary adenoma and pheo/PGL partici-
pated in the study.
Outcome: Outcomes included genetic screening and clinical characteristics.
Results:Elevengermlinemutations (five SDHB, one SDHC, one SDHD, twoVHL, and twoMEN1) and
four variants of unknown significance (two SDHA, one SDHB, and one SDHAF2) were identified in
the studied genes in our patient cohort. Tumor tissue analysis identified LOH at the SDHB locus in
three pituitary adenomas and loss of heterozygosity at theMEN1 locus in two pheochromocyto-
mas.All thepituitary adenomasofpatients affectedby SDHXalterationshaveauniquehistological
feature not previously described in this context.
Conclusions: Mutations in the genes known to cause pheo/PGL can rarely be associated with pituitary
adenomas,whereasmutationinagenepredisposingtopituitaryadenomas(MEN1)canbeassociatedwith
pheo/PGL.Ourfindingssuggestthatgenetictestingshouldbeconsideredinallpatientsorfamilieswiththe
constellation of pheo/PGL and a pituitary adenoma. (J Clin Endocrinol Metab 100: E531–E541, 2015)
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The prevalence of symptomatic pituitary adenomas(PAs) in the general population is 1:1063 to 1:1282
(1, 2), whereas the prevalence of clinically diagnosed
pheochromocytomas/paragangliomas (pheo/PGL) is
1:2500 to 1:6667 (3, 4). Although both are relatively rare
diseases, PAs and pheo/PGL can sometimes occur in the
same patient or in the same family. Coexistence of the two
diseases could be due to pure coincidence, but it is possible
that in some cases the two conditions share a common
pathogenic mechanism. Since the first description of a pa-
tient with acromegaly and pheochromocytoma in 1952
(5), 70 cases have been published with this rare disease
combination (Supplemental Tables 1–5). The simultane-
ous occurrence of these two tumor types might be ex-
plained by the following: 1) a pheo/PGL-related gene mu-
tation,which, in addition to thepheo/PGL, also causesPA,
as suggested for the SDHXmutation being involved in PA
formation (6–8); 2) a mutation in a familial PA gene that
also causes pheo/PGL; 3) a digenic disease, ie, two gene
abnormalities are present in the same patient or family
causing the two diseases; 4) a single, possibly novel, gene
causing both diseases; 5) ectopic hypothalamic hormone-
secreting adrenal tumors causing pituitary enlargement
mimicking PA; or 6) the development of a pituitary ade-
noma and a pheo/PGL in the same patient or same family
due to pure coincidence.
In the current study,we describe 39 cases of sporadic or
familial pheo/PGL and PA in which a germline genetic
analysis, loss of heterozygosity (LOH), and pathological
studies were performed. Eleven germlinemutations in five
different genes (five SDHB, one SDHC, one SDHD, two
VHL, and twoMEN1) and four germline variants of un-
known significance in three different genes (two SDHA,
one SDHB, and one SDHAF2) were identified in the stud-
iedgenes inourpatient cohort.Tumor tissue analysis iden-
tified LOHat the SDHB locus in three pituitary adenomas
andLOHat theMEN1 locus in twopheochromocytomas.
We have also identified a novel histological feature of
SDHX-related PAs.
Materials and Methods
Patients
We collected clinical data, genomic DNA, and tumor tissue,
when available, from 39 patients with pheo/PGL and PA in a
sporadic (n 19) or familial (n 20) setting. Probands from 23
aryl hydrocarbon receptor interacting protein (AIP) mutation
negative familial isolated PA (FIPA) families (defined as two or
more subjects with pituitary adenomas but no syndromic fea-
tures of other diseases such as multiple endocrine neoplasia
(MEN)-1 or Carney complex) served as controls. Neurofibro-
matosis was ruled out based on clinical criteria according pub-
lished guidelines (9). The study was approved by the local ethics
committee and all subjects gave written informed consent.
Genetic screening
Nucleic acid extraction
Genomic DNA was extracted from peripheral blood using a
BACC2 DNA extraction kit (RPN-8502; GE Healthcare) ac-
cording to the manufacturer’s protocol. DNA extraction from
formalin-fixed, paraffin-embedded pituitary or pheo/PGL tis-
sue was performed using a QIAamp DNA FFPE tissue kit
(QIAGEN). Representative tumor tissue was marked by a pa-
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thologist to avoid areas showing suboptimal preservation and
contamination with normal tissue.
Mutation testing
Sequence analysis of the AIP gene (NM_003977.2), MEN
type 1 gene (MEN1; NM_130799.2), cyclin-dependent kinase
inhibitor 1B gene (CDKN1B; coding regionNM_004064.3, up-
streamopen reading frameNM_004064.2)wasperformedusing
Sanger sequencing and multiplex ligation-dependent probe am-
plification (MLPA), as previously described (10–12). Genes im-
plicated in pheo/PGL [MYC associated factor X (MAX;
NM_002382.3), rearranged during transfection tyrosine kinase
receptor gene (RET; NM_020975.4), succinate dehydrogenase
subunit A (SDHA; NM_004168.2), succinate dehydrogenase
complex assembly factor 2 (SDHAF2; NM_017841.2), succi-
nate dehydrogenase subunit B (SDHB; NM_003000.2), succi-
nate dehydrogenase subunit C (SDHC; NM_003001.3), su-
ccinate dehydrogenase subunit D (SDHD; NM_003002.2),
transmembrane protein 127 (TMEM127; NM_017849.3), and
von Hippel-Lindau gene (VHL; NM_000551.3)] were analyzed
using a combination of next-generation sequencing, Sanger se-
quencing and MLPA, as previously described (13, 14). In addi-
tion, fumarate hydratase (NM_000143) was studied in a subset
of patients. Tissue DNA analysis with PCR and sequencing was
carried out according to standard protocols (Applied Biosys-
tems). The sequences were analyzed using Mutation Surveyor
(version 4.0.6; Softgenetics). In silico analysis of variants was
performed using the Polyphen2 (http//:genetics.bwh.harvard-
.edu) and ALAMUT 2.2.0 (http://www.interactive-biosoft
ware.com/) softwares.
Loss of heterozygosity analysis
Microsatellites D1S170 and D1S3669 for the SDHB locus
were identified on the National Center for Biotechnology Infor-
mation website (http://www.ncbi.nlm.nih.gov/) and the Univer-
sity of California, Santa Cruz Genome Browser website (http://
genome.ucsc.edu/). Details of the microsatellites at the 11q13
locus (forMEN1)were previously described (15). Simple repeats
were identified using the University of California, Santa Cruz
website and designed accordingly for the specific region (15).
The NCBI36/hg18 assembly of the human genome was used for
the localization of the markers. Fragment analysis was carried
out using standard protocols on an ABI 3730 (Applied Biosys-
tems) and analyzed using GeneMarker (version 2.20; SoftGen-
etics). All primer sequences are available on request.
Immunohistochemistry
Immunostaining forGHRHwas performed usingGHRHan-
tibody 451–7 (Lyon, France), 1:2000 dilution, as previously de-
scribed (16, 17). Pheochromocytomas of patients with the
MEN1 mutation were stained for menin using a rabbit poly-
clonal antimenin antibody (Abcam; ab2605, dilution 1:500), as
previously described (18). Mouse pancreas showing islets and
pheochromocytomas of patients without any known germline
mutation were used as a positive control. SDHA and SDHB im-
munostaining was performed using a mouse monoclonal anti-
SDHA antibody (2E3GC12FB2AE2, ab147159, dilution 1:200;
Abcam) and a rabbit polyclonal anti-SDHB antibody
(HPA002867, dilution 1:200; Sigma-Aldrich), as previously de-
scribed (19). Further immunostaining was performed using the
antimitochondrial antibody 113-1 recognizing a 60- to 65-kDa
nonglycosylated membrane protein (Merck Millipore; dilution
1:150) and an antibody directed against the endoplasmic retic-
ulum lectin 1 (ERLEC1; dilution 1:100; Novus Biological). Im-
munoreactions were performed using the automated Leica Bond
III system. For antigen unmasking, EDTA at pH 8 was used for
anti-113-1 and sodium citrate buffer (10 mM sodium citrate,
0.05% Tween 20, at pH 6) for anti-ERLEC1. The primary an-
tibody binding was visualized with the SuperSentitive immuno-
histochemistry detection system from BioGenex. Sections were
counterstained with Mayer’s hemalum before being dehydrated
and coverslipped.
Statistical analysis
The statistical analysis was performed using StatsDirect soft-
ware (Addison-Wesley-Longman). Normal distribution of the
data was tested by the Shapiro-Wilk test. The Student t test was
used to compare numerical variables. The 2 or Fisher’s exact
tests were used to compare categorical variables. The results are
reported as mean  SD. Values of P  .05 were considered
statistically significant.
Results
Clinical data
We identified 39 patients with sporadic (n  19) or
familial (n  20 from eight families) pheo/PGL and PA.
The gender distributiondidnot differ significantly (P .6)
in our cohort (18 males, 21 females) compared with the
control group (12 males, 11 females). The mean age at
diagnosis was 43.7 18.2 years (mean SD) for PA and
47.2 15.6 years for pheo/PGL (Supplemental Table 6).
There was no significant difference in age of onset of PAs
compared with the control group (35 15.4; P .08). In
the PA-pheo/PGL cohort, comparing patients with and
without mutation, no difference was identified in the age
at diagnosis of the PA [mutation positive group (n  12)
43.4 18.9 y vsmutation negative group (n 16) 44.8
17.1 y, P .8] or in the age of diagnosis of the pheo/PGL
[mutation positive group (n  15) 46.7  14.3 y vs mu-
tation negative group (n  14) 48.4  19.7 y, P  .8].
Nineteen patients had both pheo/PGL and PA,whereas
a further 20 patients had pheo/PGL or PA in a setting
detailed below. In two families (families 1 and 6), the pro-
band had both PA and pheo/PGL, whereas other family
members had either PA or pheo/PGL. In five families the
pituitary and pheo/PGL tumors occurred in the same fam-
ily but not in the same individual.One patientwith aVHL
mutation anda family historyof clear-cell renal tumor and
multiple hemangioblastomas had a PA presenting at 15
years (no typical VHL manifestations at this stage) (20).
Two patients withMEN1 mutations had a pheochromo-
cytoma. One patient had acromegaly due to a GHRH-
secreting pheochromocytoma (21).
doi: 10.1210/jc.2014-3399 jcem.endojournals.org E533
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Most PAs were lactotroph adenomas (n 15), but so-
matotroph (n 6), clinically nonfunctioning (n 5, four
of them showing positive FSH, LH or -subunit immu-
nostaining), and corticotroph (n 1) adenomaswere also
seen. Twenty patients had macroadenomas and four pa-
tients had amicroadenoma (for three patients PA size was
not available). Therewas no significant difference (P .8)
in the pituitary adenoma size compared with the control
group. Therapeutic modalities for pituitary disease in-
cluded surgery, medical therapy (cabergoline or bro-
mocriptine and somatostatin analogues), or radiotherapy.
Twelve patients needed only one therapeutic intervention,
and four patients needed two, three patients needed three,
three patients needed four, and one patient needed five
different therapeutic interventions (for three patients in-
formation on treatment modality was not available). One
patient developed pituitary apoplexy.
Sixteen patients had pheochromocytomas and 14 pa-
tients had PGLs, of which 12 were head and neck PGLs
and two were abdominal (retroperitoneal) PGLs.
Genetic screening
Germline alterations were identified in SDHA, SDHB,
SDHC, SDHD, SDHAF2, VHL, andMEN1 genes in 19
patients with pheo/PGL and/or PAs. Fourteen of the 19
patients who harbored a genetic variant were index pa-
tients. All patients harbored one genemutation except one
patient, who had a VHL mutation and an SDHA variant
of unknown significance. Twenty patients (including 10
harboring both pheo/PGL and PA) had no identifiable
mutations in any of the genes tested (Table 1 and Supple-
mental Table 6). None of the patients in our cohort had
AIP or CDKN1B mutations.
SDHX mutation
We identified 11 kindreds (including 16 patients) with
germline SDHX variants (Supplemental Table 6). Seven
families had a pathogenic SDH mutation, whereas four
had a variant of unknown significance. All patients with
SDHX mutations/variants had a pituitary macroad-
enoma. In the pituitary adenomas, in which suitable sam-
ple was available, we identified the loss of the wild-type
allele in the adenoma sample compared with the germline
DNA (Figures 1-3). In particular, patient 5was interesting
in whom the germline mutation was a large deletion af-
fecting exons6–8of theSDHBgene,whereas in the tumor
sample the whole gene was deleted with no detectable
exons 6–8 and a reduced amount of the other exons. We
identified two SDHA variants of unknown significance.
One of these (c.969CT, p.Gly323Gly) was identified in
a patient (patient 15) with a Wilms tumor (at the age of
1 y), retroperitoneal liposarcomas (32 and 40 y), a PGL in
Table 1. Genes Tested in Pheo/PGL  Pituitary Adenoma Patient Cohort
Genes
Number of Patients With
Sequence Variant
Sequence
Variant
LOH in the
Pituitary
Adenoma
LOH in
the Pheochromocytoma
SDHA 2 (2 variants)a c.969CT (p.Gly323Gly)b No LOH Not tested
c.91CT (p.Arg31Ter)
SDHB 9 (8 mutations and 1 variant) c.298TC (p.Ser100Pro) 3 LOH Tested and identified in 1 case
c.587GA (p.Cys196Tyr)
SDHB del exons 6–8
c.423  1GA
c.770dupT (p.Asn258GlufsTer17)
Variant: c.80GA (p.Arg27Gln)
SDHC 2 (2 mutations) c.380AG (p.His127Arg) NA Not tested
SDHD 2 (2 mutations) c.242CT (p.Pro81Leu) NA Not tested
SDHAF2 1 (variant) c.-52TC NA Not tested
VHL 2a c.340GC (p.Gly114Arg) No LOHc Not tested
c.589GA (p.Asp197Asn)
MEN1 2 c.1452delG (p.Thr557Ter) Not tested 2 LOH
c.783  1GA
RET 0
TMEM127 0
MAX 0
FH 0
AIP 0
CDKN1B 0
Abbreviations: FH, fumarate hydratase; NA, not available.
a One patient had two variants, a VHL and an SDHA variant.
b Further details are cited in Supplemental Table 6.
c LOH is not obligatory in VHL-related tumors [Banks RE, Tirukonda P, Taylor C, et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL)
gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res. 2006;66:2000–2011].
E534 Dénes et al Pheochromocytoma/Paraganglioma & Pituitary Adenoma J Clin Endocrinol Metab, March 2015, 100(3):E531–E541
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/100/3/E531/2840010 by U
niversity of C
ardiff - Journal of Biochem
isty Trial user on 16 Septem
ber 2019
the retroperitoneum(50y), a renaloncocytoma (50y), and
a nonfunctioning pituitary adenoma (NFPA; 53 y). His
father had an NFPA operated at 44 years and again at 74
years. His mother (no known tumors) carried the
c.969CT variant. The other SDHA variant was identi-
fied in a patientwith aVHLmutation andPA (patient 21).
We have also identified an SDHB variant (c.80GA
p.Arg27Gln, patient 17) of unknown significance. We
have tested the proband’s pheochromocytoma and
showed LOH at the SDHB locus; however, the SDHB
staining of the pheochromocytoma did not show loss of
SDHB expression. No pituitary tissue was available for
testing in this family. An SDHAF2 variant c.-52TCwas
identified in a patient with somatotroph macroadenoma
and head and neck PGL. The patient was not operated
upon and therefore no tissue is available.
We identified two families with SDH mutations in
which a family member with a PA did not carry the germ-
line SDHXmutation: family 6 with two SDHCmutation-
positive siblingshadPAand/orPGL,whereas a first cousin
had an NFPA but no SDHC mutation; and family 7 in
whom the parent and child both had SDHD mutation-
positive PGL and another child had a microprolactinoma
but no SDHD mutation (Supplemental Figure 1). These
cases are either phenocopies or could, theoretically, be
explained by a digenic disease pat-
tern in which the second disease-
causing gene has not been identified.
VHL mutation
An18-year-oldpatientwithapatho-
genic VHL mutation [c.340GC, a
missense mutation affecting a surface
amino-acid (22)], had an invasive GH-
and prolactin (PRL)-positive PA as
shown in Supplemental Table 6 and
Supplemental Figure 2 (20).
MEN1 mutation
We identified two patients (pa-
tients 22 and 23) with a germline
MEN1 mutation and pheochromo-
cytoma, whereas all the other tested
genes were normal (Supplemental
Table 6). Both pheochromocytomas
showed LOH in the MEN1 gene,
supporting, although not proving,
the pathogenic role of MEN1 in
these tumors (see Figure 4, A and B).
Although the association of pheo/
PGLs and an MEN1-like syndrome
has been described in the literature in
13 cases, in only four of these have
MEN1 mutations been identified (23–25), and none of
themhas been studied forLOH in the pheochromocytoma
tissue.
Control patients
We studied 23MEN1-, AIP-, and CDKN1B-negative
FIPA family probands without features of Carney com-
plex or a personal or family history of pheo/PGL (Supple-
mental Table 7). We analyzed their DNA for all the pheo/
PGL-related genes included in our panel to investigate the
role of these genes in FIPA families. No pheo/PGL-related
gene mutations were found in these families.
Pathological features
The PAs of patients with SDHXmutations (patients 1
and 2 from family 1, patient 4, and patient 5) were char-
acterized by intracytoplasmic vacuoles. The extent of vac-
uolization was not related to the histological type (pro-
lactinoma or NFPA) of the tumor (Figures 1–3). The
number of vacuolated cells varied from about 50% to
80% of the neoplastic cell population. Vacuoles ranged
from small and multiple (Figure 3C) to large, occupying
most of the cytoplasm and mimicking signet-ring cells
(Figure 2C). None of the vacuoles indented the nucleus as
Figure 1. Pedigree (A) and LOH (B) at the SDHB locus in the pituitary adenoma of patient 1 in
family 1 is shown. C, H&E staining of the pituitary adenoma of the proband (patient 1 in family
1) shows predominant trabecular architecture (20). D, Vacuoles at times filling the entire
cytoplasm characterize this case (arrow) (H&E, 40). E, H&E staining (20) of the pituitary
adenoma of the proband’s mother (patient 2 in family 1) also shows similar intracytoplasmic
vacuoles. F, The immunoreaction with the anti-113-1 antibody (immunoperoxidase, 20) shows
the mitochondria content. G, MRI imaging of proband’s mother’s pituitary adenoma. H, MRI
imaging of the proband’s pituitary adenoma and glomus vagale tumor. MRI, magnetic resonance
imaging.
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commonly seen with accumulation of lipids. One case
showed focal oncocytic changes identifiable on the hema-
toxylin and eosin (H&E)-stained sections.Thehistochem-
ical stain periodic acid-Schiff (PAS)/diastase-resistant pe-
riodic acid of Schiff did not reveal any glycogen
accumulation. Vacuoles were not seen in the PA of the
patient with the germline VHL mutation (without SDH
mutation) (Supplemental Figure 2). The SDHB staining of
PAs with the SDHB mutation showed either a loss of ex-
pression of SDHB or a faint expression (Figures 2D and
3E).
Because SDHX mutations are known to alter mito-
chondrial function, immunostaining was performed for a
mitochondrial membrane protein with the anti-113-1 an-
tibody. This staining documented variable accumulation
of mitochondria in SDHX mutation-positive PA cells.
Some adenomas in particular showed increased immuno-
staining compared with the other cases (Figures 1F and
3D) in keeping with the focal oncocytic changes observed
in the H&E-stained sections. Vacuoles did not appear to
be rimmed by this protein, suggesting that vacuolization is
not secondary to dilatation of mitochondria. To under-
stand whether vacuoles were the result of swelling of the
endoplasmic reticulum (ER), we immunostained our sam-
ples for theERmarkerERLEC1.Noneof the vacuoleswas
lined by this protein, indicating that they were not related
to the ER (Supplemental Figure 3).
Menin staining of the pheochro-
mocytoma samples of the patients
with MEN1 mutations showed ei-
ther no menin-positive cells or
weakly positive staining nuclei (Fig-
ure 4).
Discussion
Syndromic presentation of PA and
pheo/PGL is rare, and it is not part of
the classical multiple endocrine tu-
mor syndromes. This study de-
scribes,webelieve, the largest cohort
of patients with PAs and pheo/PGLs.
Systematic testing of this population
for alterations of the known pitu-
itary and pheo/PGL-related genes
suggest that SDH mutations play a
pathogenic role in the development
of PAs in some of these patients.
Cases of other pheo/PGL genes asso-
ciated with PA, VHL and RET, are
exceptionally rare. On the other
hand, the MEN1 mutations can
sometimes lead to pheo/PGLs, as suggested previously
(23–25), and here we present supporting LOH and im-
munostaining findings. An endocrine rather than genetic
association occurs when pheochromocytomas secrete hy-
pothalamic-releasing hormones (GHRH or CRH) mim-
icking the PA and pheo/PGL syndrome, described previ-
ously in eight cases (Supplemental Table 2). Although in
these cases only the adrenal gland harbors a tumor
whereas the pituitary usually displays hyperplasia in re-
sponse to the ectopic hormone secretion, this is a relevant
clinical differential diagnostic scenario and should be kept
in mind in patients with pituitary disease and pheo/PGLs.
In approximately half of our cases, no germline abnor-
malities were seen, suggesting either the presence of other
disease-causinggenesor the coincidental occurrenceof the
pituitary and pheo/PGL tumors.
Because this is a multicentric study with a patient co-
hort from all over theworld, with a heterogeneous genetic
background, it is difficult to estimate whether the coinci-
dence of these two tumors occurred randomly, or other,
not-yet-specified genetic factors could be playing a role.
Using the ranges of the available prevalence data for PAs
and pheo/PGLs in the general population (1–4), the co-
incidental chance for the two diseases occurring in the
same patient ranges between 1 in 2.5 million and 1 in 8.5
million subjects. In our single center (Barts), we reviewed
Figure 2. Pedigree (A) and LOH (B) at the SDHB locus in the pituitary adenoma of patient 4; the
microsatellite upstream of the mutation has also shown to be lost. C, H&E-stained section (20)
of this adenoma shows prominent vacuolar changes in most neoplastic cells; the cytoplasm
otherwise appears weakly eosinophilic. D, SDHB staining suggesting lack of strong granular
staining of the pituitary adenoma of the proband (immunoperoxidase, 20) (inset: positive SDHB
staining as positive control in a paraganglioma).
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828 patients with pituitary tumors and 150 with pheo/
PGL (26, 27). Assuming a maximum population fre-
quency of pheo/PGL of 1 in 2500, we predict that 0.33
cases in a population-based series of 828 pituitary ade-
nomapatientswouldhave apheo/PGL,whereas the actual
frequency in patients seen at our center was 2 in 828 (P
.048; Fisher’s exact test on single proportions). Likewise,
assuming the maximum population frequency of PA of 1
in 1000, we expect 0.06 cases in a population-based series
of 150 pheo/PGL patients would have a PA, whereas the
actual frequency is 2 in 150 (P .01). Both of these data
sets suggest an increased incidence.
Of the six suggested explanations for the coexistence of
PA and pheo/PGL that we outlined in the introductory
text, we could confirm the following options: 1) a pheo/
PGL-related gene causes PA, 2) a pituitary gene causes
pheo/PGL, 5) ectopic hypothalamic hormone synthesis in
a pheochromocytoma, and probably one or more families
in our cohort match option, and 6) representing pure co-
incidence. Regarding option 3, we have not found any
patients with mutations in two genes, such as a classical
pheo/PGL and a pituitary tumor gene. In addition, we
found LOH at the SDH locus in pituitary adenomas and
at the MEN1 locus in pheochromocytomas, suggesting,
although not proving, that in these patients a single gene
is responsible for both tumors. Exome or whole-genome
sequencing studies in the future might find novel genes
causing both diseases (option 4). In our cohort 19 patients
(48%) had a germline alteration, among them 17 (43%)
withagenetic variant in thepheo/PGLgenes.Large studies
showed that about one-third of pheo/PGL patients (most
familial cases and 10%–20% of the sporadic cases) carry
a germline mutation in RET, VHL,NF1, SDHA, SDHB,
SDHC, SDHD, SDHAF2, MAX, or TMEM127 genes
(28, 29), suggesting that our cohort may have a slightly
higher percentage of germline alterations.
The clinical features of the published cases of the asso-
ciation of pituitary disease and pheo/PGLs are summa-
rized in the Supplemental Material (Supplemental Tables
1–5).More recently, three screening studies havebeenper-
formed.One of them screened a groupof patients (26 PGL
patients and eight carriers) with a particular SDHD mu-
tation due to a founder effect for the presence of a PA.One
GH-secreting macroadenoma and three nonfunctioning
microadenomas (suggested to be incidentalomas) were di-
agnosed in this patient cohort. No LOHwas found at the
SDHD locus in the GH-secreting PA (30). In the second
study, 309 PAs were screened for SDH mutations and a
macroprolactinoma with two different somatic SDHA
mutations with normal sequence in the germline (31) was
Figure 3. Pedigree (A) and sagittal and coronal magnetic resonance images of the pituitary adenoma (B) are shown. C, H&E-stained section (20)
shows that the tumor of patient 5 contains multiple vacuoles. D, The immunoreaction with the anti-113-1 antibody (immunoperoxidase, 20)
highlights the mitochondria content. E, SDHB immunostaining shows loss of expression in neoplastic cells, whereas endothelial cells (arrow) retain
the expression (immunoperoxidase, 20). Loss of the SDHB gene in germline and pituitary tumor tissue in patient 5. F, Germline DNA shows a
deletion affecting MLPA SDHB probes 6–8 in DNA derived from leukocytes. G, In pituitary adenoma tissue, a complete loss of genetic material at
the SDHB probes 6–8 area and heterozygous loss of SDHB probes 1–5.
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found. In the third study, screening has been performed in
SDHX-mutated patients for nonpheo/PGL tumors. Two
patients with SDHDmutations were found to have a PA,
and in one of these cases, LOH at the SDHD locus was
shown in the macroprolactinoma (32). Whether it is cost
effective to measure prolactin in patients with pheo/PGLs
needs to be studied further.
Summarizing our cases combined with the cases avail-
able in the literature (altogether 109 cases since 1952), we
have tried to identify any particular features for each gene
alteration for the tumor not classically associated with
that gene.Twenty caseshavea confirmedSDHXmutation
with pituitary adenoma [(two SDHA (8, 31), eight SDHB
(33, 34), two SDHC (35), and eight SDHD (30, 32, 36,
37)]. The patients with an SDHmutation had various PA
types (Supplemental Tables 3 and 6): nine macroprolacti-
nomas, three somatotroph adenomas, and five NFPAs
have been described. In three cases the PA subtypes could
not be classified.All the PAsweremacroadenomas, except
for three nonfunctioning microadenomas (possibly inci-
dentalomas). The patients needed one to four therapeutic
interventions. Five patients needed a single therapeutic
intervention, five patients needed two, one patient needed
three, and two patients needed four therapeutic interven-
tions. Of the 109 patients, five patients had RET muta-
tions (38–41); two cases with acromegaly, two cases with
prolactinoma, and one NFPA (one macroadenoma and
onemicroadenoma, and in three cases the adenoma size is
not available). Four patients needed one therapeutic in-
tervention (three surgeries and one medical treatment),
whereas one patient needed medical therapy after trans-
sphenoidal resection of the pituitary tumor. Two patients
had a VHL mutation (20), one with a PRL and one with
a GH- and PRL-secreting adenoma. Six patients had a
confirmed MEN1 mutation and pheo/PGL (23–25): five
patients with pheochromocytoma and one head and neck
PGL.
Wehave identified a novel feature of the PAs of patients
harboring SDHX variants. The adenoma tissues show ex-
tensive vacuolization of cytoplasm with features reminis-
cent of signet-ring cells or physalipherous cells (42). The
origin of vacuoles remains unclear. Lipid and glycogen
accumulation was suggested in the literature, but none of
the vacuoles indented the nucleus as commonly seen in
Figure 4. A, LOH analysis at the MEN1 locus of the pheochromocytoma of patient 22 and patient 23 (B). Underlined microsatellite results identify
markers that show a reduction in peak height in the pheochromocytoma sample compared with blood, indicating LOH but suggesting that some
nontumoral tissue was also retained in the operated samples. C, Pheochromocytoma of patient 22 shows a loss of menin staining (inset: positive
menin staining in mouse Langerhans islet). D, The menin staining of the pheochromocytoma of patient 23 shows some weakly positive staining
nuclei (inset: positive menin staining in a sporadic pheochromocytoma used as a positive control).
E538 Dénes et al Pheochromocytoma/Paraganglioma & Pituitary Adenoma J Clin Endocrinol Metab, March 2015, 100(3):E531–E541
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/100/3/E531/2840010 by U
niversity of C
ardiff - Journal of Biochem
isty Trial user on 16 Septem
ber 2019
cells with accumulation of lipids and the histochemical
stain PAS/diastase-resistant periodic acid of Schiff did not
reveal any glycogen accumulation. The vacuoles also do
not resemble particle-rich cytoplasmic structures, de-
scribed in epithelial neoplasms (43). Vacuolization of the
nontumorous adenohypophyseal cells has been described
in cases of fatal hypothermia in two separate studies (44,
45). Ishikawa et al (44) suggested that the vacuoles are
different from dilated cisternae of rough ER and from
distended Golgi apparatus, which are the result of castra-
tion or gonadal dysfunction and raised the possibility that
they are lipid droplets due to metabolic dysfunction ini-
tiated by the hypothermia. Doberentz et al (45) also noted
cytoplasmic vacuolation of the anterior pituitary cells in
the caseofhypothermia, and they suggested that this could
be due to gradually developing tissue hypoxia. Oncocytic
PAs have recently been identified to contain somatic mu-
tations affectingmitochondrial respiratory chain complex
I, but these tumors do not show the vacuolar changes we
have identified in the SDH-related samples (46).
Inactivation of succinate dehydrogenase or VHL can
lead to activation of the hypoxia inducible factor pathway
and a pseudohypoxic state. Indeed, we have shown in-
creasedhypoxia inducible factor-1 in anSDHD-mutated
case linked to pituitary adenoma (37). It is not known
whether the vacuoles seen in the SDH-related tumors are
due to thepseudohypoxic state, butwedidnotobserve this
phenomenon in the VHL mutation-related PA (Supple-
mental Figure 2).
Immunostaining for a mitochondrial membrane pro-
tein or for an ER marker did not prove that the vacuoles
arise from these organelles. We attempted electron mi-
croscopy to identify the nature of the vacuoles, but this
was inconclusive due to the poor preservationof formalin-
fixed tissue recovered from paraffin (data not shown).
These vacuoles were not specifically described in the stud-
ies of recently published SDHXmutations associatedwith
PAs, but based on the available histological pictures, the
presence of vacuoles cannot be ruled out (8, 31, 37). Vac-
uoleshavebeendescribed inSDHBmutation-related renal
carcinoma and were attributed to giant mitochondria
(47), but the clear cytoplasm observed in these tumors can
also represent glycogen or fat (48). Large cytoplasmic vac-
uoles suggested to be mitochondria based on electron mi-
croscopy have previously been described in PAs (49), pos-
sibly due to ischemia. Acidophil stem cell adenomas can
also contain paranuclear vacuoles resulting fromgiantmi-
tochondria (50).
The activity of certainmitochondrial enzymes involved
in oxidative phosphorylation is decreased in cancer cells
compared with normal tissue (51). Taking into account
that succinate dehydrogenase enzymes, being part of the
mitochondrial complex II, play an important role in mi-
tochondrial function, mutations that affect the activity of
these enzymesmight have a role inmitochondria dysfunc-
tion (52). We believe that the vacuoles represent a hall-
mark of PA in patients with the SDHX variant, but their
nature remains to be further investigated. In addition, fur-
ther study of the metabolic pathways in SDH-related en-
docrine tumors are awaited.
Our study has several shortcomings. First of all, being
a specialist pituitary and adrenal center with an interest in
familial pituitary adenomas, our centermight attractmore
unusual genetic conditions, therefore representing a
higher prevalence of these cases. In a significant portion of
the patients, tumor samples were not available, often due
to the lack of surgical intervention; therefore, no appro-
priate material was available for LOH or to study in fur-
ther detail the unusual histological phenotype in the PAs.
In summary, germline mutations were identified in the
studied genes in 11 of 27 kindreds with the combination
of pheo/PGL and PAs. LOH at the SDHB locus in the PA
samples and LOH at the MEN1 locus in the pheochro-
mocytoma samples was demonstrated, suggesting, al-
though not proving, the pathogenic role of these genes in
these nonclassically disease-specific tissues. In addition,
we noted intracytoplasmic vacuoles in PAs of patients af-
fected by SDH mutations. Together with the single case
reports available in the literature, this large cohort sup-
ports the hypothesis that in some families SDHmutations
may have a role in PA formation and MEN1 mutations
may have a role in the development of pheochromocy-
toma. Whether screening for PAs in SDHX patients is
warranted needs to be studied in the future, but our find-
ings suggest that genetic testing for germline mutations in
SDHX andMEN1 should be considered in patients with
the constellation of pheo/PGLs and PAs.
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